Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox in Chronic Exertional Compartment Syndrome
NCT03922139Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in Chronic Exertional Compartment Syndrome (CECS), sponsored by University of Wisconsin–Madison. Primary endpoints: Percentage of Relief of Pain at 6 months, Number of Participants With Lower Extremity Weakness at 6 months and 1 more. Started Oct 2019; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
Chronic Exertional Compartment Syndrome (CECS)
Beyond the preview
Go deeper on NCT03922139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922139.